



2 August 2022
NZX/ASX Market Release

a2MC notes and responds to media speculation

The a2 Milk Company (a2MC, the Company) notes a media article that has appeared online in the Australian Financial Review today that suggests that the Company is nearing approval from the US Food and Drug Administration (FDA) to allow a2MC to import infant milk formula products into the US and that such approval could be received “as soon as this week”.

The Company wishes to confirm that while we have been informed by the FDA that our application is under active review, at this stage there is no certainty as to the outcome of the application or the timing of any approval.

Authorised for release by

David Bortolussi
Managing Director and Chief Executive Officer
The a2 Milk Company Limited

For further information, please contact:

Investors / Analysts

David Akers
Group Head of Investor Relations and Sustainability
M +61 412 944 577
david.akers@a2milk.com

Rebecca Culbertson
Senior Analyst Investor Relations
M +61 400 955 295
rebecca.culbertson@a2milk.com

Media

Rick Willis
M +61 411 839 344
rick@networkfour.com.au

Media – New Zealand

Barry Akers
M +64 21 571 234
akers@senescallakers.co.nz